Novo Nordisk’s inventory retains falling even when the information is nice, and CEO Mike Doustdar simply admitted why. Eli Lilly is thrashing Novo at its personal recreation.
Doustdar sat down with CNBC’s Jim Cramer this week to elucidate the disconnect. Novo, well-known for its GLP-1 treatment Ozempic, raised its full-year gross sales steering on August 4, narrowing its projected annual decline from 8% to three% on the midpoint. Traders offered anyway. NVO shares dropped roughly 6% that day.
A Beat That Nonetheless Misplaced
Doustdar walked by way of the mathematics on air. Novo slashed costs on Ozempic and Wegovy final yr to widen affected person entry, and quantity hasn’t caught up but to offset these cuts. He in contrast it to primary arithmetic. Halving a value means you want double the quantity simply to interrupt even, and quantity by no means doubles on day one.
That hole between falling common income per prescription and rising affected person counts is precisely what has traders nervous. Novo’s weight problems and diabetes medicine now make up round 90% of its enterprise, in comparison with about 60% at Eli Lilly, leaving Novo extra uncovered to any pricing or aggressive shock in that single class.
Doustdar’s Concession
Oral Wegovy sits on the heart of this story. Novo launched the capsule model of its weight-loss drug in January, and it shortly grew to become one of many fastest-selling medicine in pharmaceutical historical past. Medical doctors have already written greater than 5 million prescriptions for it, and 1.5 million sufferers now take it worldwide. That quantity makes Novo’s inventory response even more durable to elucidate on the floor.
Cramer pressed him on why Eli Lilly’s inventory rally has outrun Novo’s regardless of a much less dominant capsule. Doustdar didn’t dodge the query.
“Eli Lilly has been gaining market share. And so they’re extra diversified than Novo Nordisk… there isn’t a secret that Lilly has been fairly profitable truly in having quantity uptake and market share uptake above and past Novo.”
He argued Lilly’s advert marketing campaign leans on an older, lower-dose model of Wegovy for comparability. Novo’s newer high-dose formulation matches Lilly’s efficacy, in keeping with Doustdar. That dispute sits on the heart of Novo’s lawsuit towards Lilly over its promoting claims.
The Capsule Nonetheless Wins on Paper
The inventory droop hasn’t slowed the capsule’s numbers. In Novo’s personal trials, the capsule cuts weight by 17%, towards 12% for Lilly’s rival capsule, although the 2 medicine haven’t confronted off head-to-head. Doustdar known as it the very best product launch in pharmaceutical historical past, a declare that’s laborious to dispute on quantity alone.
Doustdar is betting that two straight quarters of enhancing tendencies will finally pull the inventory together with them. Whether or not that wager pays off is determined by a easy race. Affected person quantity must outrun the worth cuts quick sufficient to persuade Wall Avenue the reset is definitely over.
The publish Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Beneficial properties as Inventory Slumps appeared first on BeInCrypto.